Primary Cutaneous Marginal Zone Lymphoma: A Comprehensive Review

Primary cutaneous marginal zone lymphoma (PCMZL) represents a subset of primary cutaneous B-cell lymphomas (PCBCL) and an even smaller subset of all cutaneous lymphomas. Due to PCMZL’s indolent nature, the differentiation between PCMZL and other more aggressive PCBCLs can be challenging and result in the delay of diagnosis and treatment. The diagnosis of PCMZL requires clinical evaluation combined with immunohistochemical analysis to differentiate it from other lymphoma and non-lymphoma pathologies. The condition’s wide range of treatment options, including novel therapies, have led to various outcomes for patients diagnosed with PCMZL. This comprehensive review article emphasizes the clinical presentation and the methods of diagnosis, including appropriate pathologic evaluation, differentiating factors from other non-PCMZL conditions, and current treatment options for PCMZL.

Authors

Institutions

Publication Details

Journal
Academic Dermatology
Published
2025-07-18
DOI
https://doi.org/10.18061/ad.v3i1.9994
Primary Topic
Cutaneous lymphoproliferative disorders research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Primary Cutaneous Marginal Zone Lymphoma: A Comprehensive Review

Kirsten M. Johnson, Catherine G. Chung, Teja Mallela, Brittany Dulmage et al.
Academic Dermatology
Cutaneous lymphoproliferative disorders research
article

Primary Cutaneous Marginal Zone Lymphoma: A Comprehensive Review

Kirsten M. Johnson, Catherine G. Chung, Teja Mallela, Brittany Dulmage, Nassim Idouraine, Jordyn Puccio, Matthew Gallardo
article en

Abstract

Primary cutaneous marginal zone lymphoma (PCMZL) represents a subset of primary cutaneous B-cell lymphomas (PCBCL) and an even smaller subset of all cutaneous lymphomas. Due to PCMZL’s indolent nature, the differentiation between PCMZL and other more aggressive PCBCLs can be challenging and result in the delay of diagnosis and treatment. The diagnosis of PCMZL requires clinical evaluation combined with immunohistochemical analysis to differentiate it from other lymphoma and non-lymphoma pathologies. The condition’s wide range of treatment options, including novel therapies, have led to various outcomes for patients diagnosed with PCMZL. This comprehensive review article emphasizes the clinical presentation and the methods of diagnosis, including appropriate pathologic evaluation, differentiating factors from other non-PCMZL conditions, and current treatment options for PCMZL.

Academic DermatologyVol. 3(1)
The Ohio State University Wexner Medical Center (US), The Ohio State University (US)
Openalex Percentile: Top 47%
Cutaneous lymphoproliferative disorders research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.